This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Syros Pharmaceuticals’s 8K filing here.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.
Featured Articles
- Five stocks we like better than Syros Pharmaceuticals
- P/E Ratio Calculation: How to Assess Stocks
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
- How to Use the MarketBeat Stock Screener
- Freeport-McMoRan, Copper Demand Short-Term Pain, Long-Term Gain
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Time to Load Up on Home Builders?
